US/UK/Canada

Share

Contacts

  • General Press Enquiries
    For general press enquiries please contact the AbbVie Corporate Communications team at UKMediaRelations@abbvie.com or call us on 01628 925200
    01628 925200
    https://twitter.com/abbvieuk
    • Pick a time period -
    Tags ( Active)

    MHRA Grants Conditional Marketing Authorisation for Tepkinly[®]▼(epcoritamab) as a Bispecific Treatment for Adults with Relapsed or Refractory DLBCL After Two or More Lines of Systemic Therapy

    PRESS RELEASE - For UK consumer, medical and trade media only · Diffuse large B-cell lymphoma (DLBCL) is an aggressive sub-type of non-Hodgkin’s lymphoma, with nearly 5,500 new diagnoses in the UK each year[1] · Bispecific antibodies represent a new class of therapies that work by introducing a local immune cell to a cancer cell, enabling the immune cell to attack and destroy the cancer[2]  · As the first and only subcutaneous bispecific injection, epcoritamab could offer eligible patients an additional treatment option[3] MAIDENHEAD, UK, [23 October 2023] – AbbVie (NYSE:

    AbbVie’s AQUIPTA[®]▼ (atogepant) Is Now Available In Scotland For The Prevention Of Migraines In Adults

    PRESS RELEASE - For UK consumer, medical and trade media only · The Scottish Medicines Consortium (SMC) has accepted AQUIPTA[®] (atogepant), the oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for restricted use within NHS Scotland.[1] · The decision follows the Medicines and Healthcare products Regulatory Agency (MHRA) granting the marketing authorisation of atogepant in Great Britain on 30[th] August 2023 for the prophylaxis of migraine in adults who have at least four migraine days per month.[2] · Atogepant demonstrated significant reduction

    AbbVie’s AQUIPTA[®]▼(atogepant) receives MHRA marketing authorisation for the prevention of migraines in adults

    PRESS RELEASE - For UK consumer, trade and medical media only · The oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) is licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain for the prophylaxis of migraine in adults who have at least four migraine days per month.[1] · The marketing authorisation is based on results from two pivotal Phase 3 studies in which the treatment demonstrated significant reduction in mean monthly migraine days from baseline across 12 weeks.[1-5] · The news closely follows the European

    SMC Accepts RINVOQ[®]▼ (upadacitinib) as a Treatment Option for Adults with Moderately to Severely Active Crohn’s Disease in Scotland

    PRESS RELEASE - For Scottish Consumer, Medical and Industry Trade Media Only · Upadacitinib is the first janus kinase (JAK) inhibitor that will be available as a once daily pill for the treatment of Crohn’s disease (CD) on the NHS in Scotland, offering a new option to adults who continue to have moderate to severe CD symptoms despite treatment with conventional or biological therapies[1] · Scotland has one of the highest incidence rates of CD in the UK, at 12.3% (2019).[2] Often first diagnosed in those aged 20-30, it is estimated to affect over 12,500 adults in Scotland, a figure

    NICE Recommends RINVOQ[®]▼(upadacitinib) as a Treatment Option for Moderately to Severely Active Crohn’s Disease

    PRESS RELEASE - For UK Consumer, Medical and Industry Trade Media Only · Upadacitinib is the first janus kinase (JAK) inhibitor that will be available for the treatment of Crohn’s disease (CD) in England and Wales, offering a new option that is taken as a once daily pill to those who continue to have moderate to severe CD symptoms despite treatment with conventional or biological therapies[1] · CD is a chronic condition associated with inflammation of the digestive system.[2 ]Often first diagnosed in those aged 20-30,[2,3,4] it is estimated to affect over 155,000 adults in the UK.[

    MHRA Approves RINVOQ[®]▼ (upadacitinib) as First Oral Advanced Therapy to Treat Adults with Moderately to Severely Active Crohn's Disease

    PRESS RELEASE - For UK Consumer Health, Medical and Trade media only · This approval for Great Britain marks the first marketing authorisation globally for the use of upadacitinib, a janus kinase (JAK) inhibitor, in Crohn's disease (CD). This follows upadacitinib's approval in ulcerative colitis last year · Over 155,000 adults are estimated to live with CD in the UK,[1,2 ]a chronic, progressive condition of the digestive system[3,4] that causes a significant physical, emotional and economic burden on people living with it[5,6] · In the UK, people with CD were hospitalised

    Scottish Medicines Consortium (SMC) Extends Advice Accepting RINVOQ®▼(upadacitinib) For Treatment of Adults with Moderate Rheumatoid Arthritis

    · Upadacitinib, a once daily pill, which was previously accepted by the SMC for restricted use for the treatment of severe rheumatoid arthritis (RA) is now available for people with moderate RA in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). It has been recommended for restricted use in adults with moderate disease (a disease activity score [DAS28] of 3.2 to 5.1) when intensive therapy with 2 or more conventional DMARDs has not controlled the disease well enough. Upadacitinib may be used as monotherapy

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe